LAST 0.030
CHANGE 0.000
LAST: 0.030
CHANGE: 0.000
FSE: 18H

Stephen Van Deventer

Chairman & Chief Executive Officer 

Mr. Van Deventer is an experienced business person and corporate director. Specialising in international corporate relations and business development over the last thirty years, Mr. Van Deventer has focused on launching small to medium-sized companies into the public markets in Canada, the United States and Europe. He has also owned and operated private businesses.

Mak Jawadekar Ph.D.

President & Chief Science Officer  

Dr. Jawadekar worked at Pfizer Inc. in Groton-New London, Connecticut, for 28 consecutive years. His most recent position was as a Director of Portfolio Management at Pfizer Inc. He was responsible for Drug Delivery Technology Assessment function involving external ‘Drug Delivery’ technologies. He has extensive experience in creating and cultivating external partnerships and alliances for drug delivery technologies. He began his professional career at Pfizer Central Research in early 1982, after having completed his Ph.D. in Pharmaceutics at the University of Minnesota.

Linnéa Olofsson Ph.D.


Dr. Olofsson is an accomplished biophysicist with 12 years of laboratory research experience in academia, and 3 years working in the private sector as scientific support and equipment sales. She successfully advances science by providing counsel and training to the scientific community, contributing to executing strategic marketing plans by working in conjunction with the sales team members to identify and qualify sales leads through technical discussions. Dr. Olofsson closely collaborates with corporate strategic decision-making processes to penetrate new market applications to increase return on investment.

Kathleen Rokita CPA


Ms. Rokita is a CPA and Principal with Somerset CPA’s P.C. Kathy is a finance, operations, and strategy-focused executive having extensive experience with large medical groups. Her involvement includes business development, information reporting, analytics, and improvements in financial performance and operational processes. She has a background in treasury management, budgeting, as well as mergers and acquisitions. Kathy has been appointed to PreveCeutical’s audit committee. Kathy also selflessly dedicates time to volunteering as a board member for St. Vincent Hospital Foundation and Angelman Syndrome Foundation, where she served as Treasurer and President of the Board of Directors.

C. Evan Ballantyne


Mr. Ballantyne has extensive executive leadership experience and has spent the last 20 years as a public and private company Chief Financial Officer in the healthcare industry. He was most recently the CFO of OncXernaTherapeutics Inc. where he worked to advance partnering opportunities for the company's biomarker program. Prior to OncXerna, Ballantyne was CFO at Orchestra BioMed Inc. where he assisted with the closing of two equity financing rounds with proceeds of $57 million. At Orchestra, he also helped close a global partnership deal valued at more than $200 million.

Sign up for the latest news and updates